Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab
- Sponsor
- Pusan National University Hospital
- Study ID
- NCT01810042
- Phase
- PHASE4
- Status
- Completed
Conditions
- Exudative Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ranibizumab — DRUG0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
Study Details
Exudative age-related macular degeneration (ARMD) is complicated by choroidal neovascularization (CNV). Although anti-vascular endothelial growth factor treatment is the gold standard treatment, recurrence is the main limitation of the treatment. The changes of the CNV vascular structure is expected to provide information regarding recurrence. In the eyes that the vascular structure is clearly seen in indocyanine green angiography (ICGA), the vascular changes after ranibizumab injections will be investigated prospectively.
Key Dates
- First listed
- Mar 13, 2013
- Start date
- Oct 31, 2010
- Status verified
- Mar 2016
- Primary completion
- Feb 28, 2013
- Completion
- Feb 28, 2013
Study Design
- Enrollment
- 49 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: ranibizumab0.5mg of ranibizumab is injected into the vitreous cavity monthly 3 times for the 3 months then pro-re-nata (PRN) for following 3 months.
Primary Outcome Measure
Caliber of Choroidal New Vessel (CNV) [ Time Frame: 6 months ]